Global cannabis illegality has blocked access to more than 140 different, naturally derived cannabinoid molecules for decades, but rapidly progressing legalization in countries around the world is unlocking access to these molecules. These cannabis-derived molecules represent an unprecedented range of new Active Pharmaceutical Ingredients (APIs) which provide tremendous new research and development opportunities for the global pharmaceutical industry, and they have the power to lead to revolutionary new medicines that dramatically improve global human health.
Seven10 – the pharmaceutical manufacturing division of Pure Jamaican – was founded specifically to help the world’s leading pharmaceutical manufacturers and scientists create this revolutionary new generation of medicines. Though a phased, scalable, vertically integrated, Jamaica-based group of operating companies with GACP and cGMP-compliant facilities, we intend to be the largest cultivator, refiner and distributor of pharmaceutical-grade cannabinoid molecules and revolutionary CPG products globally.